Abramson Cancer Center at Penn Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).
Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.
Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.
Top-decile sponsor footprint
Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
402 total, page 4 of 9
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma
NCT05448196
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
NCT04873895
Text-based Intervention to Minimize the Time Burden of Routine Cancer Care
NCT05134636
Choice Architecture and Mailed Colorectal Cancer Screening Outreach in a Community Health Setting
NCT04711473
Breast Cancer Outreach Among Primary Care Patients
NCT05089903
STEP Together: An Effectiveness-Implementation Study of Social Incentives and Physical Activity
NCT04942535
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
NCT04867850
Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches
NCT04812795
Low-Level Laser in Head and Neck Chronic Lymphedema
NCT04482855
'Penny', a SMS Text-based Chatbot Intervention for Medication Adherence and Side Effect Management Among Patients With GI Cancers
NCT05113264
Young Adults' Reactions to Low Nicotine Cigarette Advertising
NCT04906148
Improving Tobacco Treatment Rates for Outpatient Cancer Patients Who Smoke
NCT04737031
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
NCT04798664
Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant
NCT04118530
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
NCT04735068
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
NCT04736472
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
NCT04737265
An Analysis of Medication Adherence Using Televideo and Telephonic Monitoring and Utilization of an Education Protocol
NCT06696521
Functional Lung Imaging With DECT and 4DCT
NCT04702607
FDA Cigarette Warning Labels: Eye Tracking Study
NCT04936724
PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers
NCT04616768
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
NCT04288687
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
NCT03685331
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
NCT06604247
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
NCT04429321
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
NCT04353973
Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study
NCT04361240
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
NCT03519308
Cigar Packaging Study
NCT04605874
Penn Biobank Return of Research Results Program
NCT04242667
GeoScan and Remote Geo Smoking Study: Neural and Behavioral Correlates of Smokers' Exposure to Retail Environments
NCT04279483
Cigarette Packaging of Low Nicotine Cigarettes
NCT03802019
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
NCT04023110
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
NCT03781960
Cardiovascular Effects of CART Cell Therapy
NCT04026737
A Trial of Behavioral Economic Interventions Among Food Pantry Clients
NCT04011384
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
NCT03693846
Cardiovascular Function in Acute Leukemia
NCT03760237
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
NCT03495713
Buddy Relationships in DermatoloGic Excisions for Skin Cancer
NCT04036344
A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer
NCT03616522
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
NCT03573986
In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer
NCT03492164
Avelumab/Gemcitabine in Sarcomatoid RCC
NCT03483883
Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy
NCT03535987
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
NCT03934606
Genetics and Heart Health After Cancer Therapy
NCT03510689
Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
NCT03087760
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
NCT03215264
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
NCT03300921
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 113 |
| Phase 2 | 62 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Abramson Cancer Center at Penn Medicine pipeline
74 recruiting of 402 indexed (18% open); 235 completed (58%).
Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide
Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 402 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of Maryland, Baltimore · 18% recruiting · 560 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this Abramson Cancer Center at Penn Medicine page
402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.
- 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.